RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes

      한글로보기

      https://www.riss.kr/link?id=A107923281

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      In an aging society in the world, dementia that leads to pain in patients and their families has become a common disease in our lives. Among dementia, Alzheimer’s disease (AD) is the most commonly shown disease. Various causes of the disease have been proposed and amyloid hypothesis insists that the toxic amyloid-β (Aβ) species could be the major risk factor of the onset and progression of AD. In this perspective, clearance of Aβ species from the brain by regulating the activity of amyloid degrading enzymes (ADE), including neprilysin and matrix metalloproteinases, could be a potent treatment for AD. Therefore, the structures and functions of these enzymes along with biological molecules in the brain would be important to understand the pathogenesis of AD and develop an effective medication for the disease. In this review, multiple ADE with biological molecules which could affect the activities and/or expression of the enzymes are summarized.
      번역하기

      In an aging society in the world, dementia that leads to pain in patients and their families has become a common disease in our lives. Among dementia, Alzheimer’s disease (AD) is the most commonly shown disease. Various causes of the disease have be...

      In an aging society in the world, dementia that leads to pain in patients and their families has become a common disease in our lives. Among dementia, Alzheimer’s disease (AD) is the most commonly shown disease. Various causes of the disease have been proposed and amyloid hypothesis insists that the toxic amyloid-β (Aβ) species could be the major risk factor of the onset and progression of AD. In this perspective, clearance of Aβ species from the brain by regulating the activity of amyloid degrading enzymes (ADE), including neprilysin and matrix metalloproteinases, could be a potent treatment for AD. Therefore, the structures and functions of these enzymes along with biological molecules in the brain would be important to understand the pathogenesis of AD and develop an effective medication for the disease. In this review, multiple ADE with biological molecules which could affect the activities and/or expression of the enzymes are summarized.

      더보기

      참고문헌 (Reference)

      1 M. G. Savelieff, 119 : 1221-, 2019

      2 D. Galimberti, 25 : 1181-, 2016

      3 B. Eftekharzadeh, 99 : 925-, 2018

      4 F. Monacelli, 9 : 670-, 2017

      5 M. G. Savelieff, 8 : 856-, 2013

      6 M. O. Grimm, 5 : 98-, 2013

      7 H. R. Parri, 82 : 931-, 2011

      8 N. Kim, 2020 : 2010728-, 2020

      9 P. Anand, 20 : 1175-, 2012

      10 K. Sharma, 20 : 1479-, 2019

      1 M. G. Savelieff, 119 : 1221-, 2019

      2 D. Galimberti, 25 : 1181-, 2016

      3 B. Eftekharzadeh, 99 : 925-, 2018

      4 F. Monacelli, 9 : 670-, 2017

      5 M. G. Savelieff, 8 : 856-, 2013

      6 M. O. Grimm, 5 : 98-, 2013

      7 H. R. Parri, 82 : 931-, 2011

      8 N. Kim, 2020 : 2010728-, 2020

      9 P. Anand, 20 : 1175-, 2012

      10 K. Sharma, 20 : 1479-, 2019

      11 C. M. Huber, 61 : 265-, 2018

      12 C. Hureau, 91 : 1212-, 2009

      13 J. A. Duce, 92 : 1-, 2010

      14 Y. H. Hung, 15 : 61-, 2010

      15 K. P. Kepp, 112 : 5193-, 2012

      16 E. L. Que, 108 : 1517-, 2008

      17 S. Miranda, 62 : 633-, 2000

      18 A. I. Bush, 26 : 207-, 2003

      19 J. Hardy, 20 : 154-, 1997

      20 D. J. Selkoe, 81 : 741-, 2001

      21 A. J. Stock, 15 : 240-, 2018

      22 G. Evin, 23 : 1285-, 2002

      23 N. N. Nalivaeva, 2012 : 383796-, 2012

      24 J. Cummings, 7 : e12179-, 2021

      25 M. Tolar, 12 : 95-, 2020

      26 R. A. Marr, 6 : 187-, 2014

      27 R. J. Baranello, 12 : 32-, 2015

      28 S. Moss, 204 : 19-, 2018

      29 C. Oefner, 296 : 341-, 2000

      30 S. Moss, 594 : 327-, 2020

      31 A. Bayes-Genis, 68 : 639-, 2016

      32 M. A. Bowes, 236 : 801-, 1986

      33 E. Hellstrom-Lindahl, 29 : 210-, 2008

      34 E. G. Erdos, 3 : 145-, 1989

      35 M. A. Kerr, 137 : 477-, 1974

      36 R. A. Skidgel, 5 : 769-, 1984

      37 S. Howell, 16 : 647-, 1995

      38 A. Bayes-Genis, 65 : 657-, 2015

      39 M. Packer, 20 : 973-, 2018

      40 P. S. Jhund, 102 : 1342-, 2016

      41 D. J. Campbell, 5 : 257-, 2018

      42 N. Iwata, 6 : 143-, 2000

      43 T. Kim, 2011 : 857368-, 2011

      44 H. Kanemitsu, 350 : 113-, 2003

      45 M. Maruyama, 57 : 832-, 2005

      46 M. Huttenrauch, 44 : 1291-, 2015

      47 R. A. Marr, 22 : 5-, 2004

      48 M. H. Mohajeri, 34 : 717-, 2009

      49 R. Poirier, 24 : 475-, 2006

      50 W. J. Meilandt, 29 : 1977-, 2009

      51 L. Devi, 8 : 19-, 2015

      52 J. Morales-Corraliza, 36 : 4248-, 2016

      53 H. Yang, 62 : 1609-, 2018

      54 C. Klein, 6 : 136-, 2018

      55 H. J. Lim, 24 : 1302-, 2013

      56 C. Schmid, 130 : 57-, 2005

      57 P. Muangman, 200 : 208-, 2005

      58 M. O. Grimm, 13 : 75-, 2014

      59 M. O. W. Grimm, 18 : 2764-, 2017

      60 M. Mital, 57 : 6193-, 2018

      61 D. K. Kim, 39 : 625-, 2014

      62 Z. Z. Sun, 31 : 277-, 2009

      63 M. B. Goncalves, 37 : 1182-, 2013

      64 R. P. Verma, 15 : 2223-, 2007

      65 H. Nagase, 69 : 562-, 2006

      66 C. A. Kontogiorgis, 12 : 339-, 2005

      67 M. Cheng, 43 : 369-, 2000

      68 J. Gross, 48 : 1014-, 1962

      69 G. S. Lazarus, 159 : 1483-, 1968

      70 J. M. Freije, 269 : 16766-, 1994

      71 M. A. Stolow, 7 : 1471-, 1996

      72 A. Sellers, 171 : 493-, 1978

      73 E. D. Harris Jr., 258 : 566-, 1972

      74 A. I. Sapolsky, 53 : 1044-, 1974

      75 R. Breathnach, 15 : 1139-, 1987

      76 P. Basset, 348 : 699-, 1990

      77 A. Sellers, 189 : 521-, 1980

      78 A. B. de Coignac, 267 : 3323-, 2000

      79 H. Sato, 370 : 61-, 1994

      80 H. Will, 231 : 602-, 1995

      81 T. Takino, 270 : 23013-, 1995

      82 X. S. Puente, 56 : 944-, 1996

      83 D. Pei, 274 : 8925-, 1999

      84 D. Pei, 9 : 291-, 1999

      85 Z. Werb, 142 : 361-, 1975

      86 J. Cossins, 228 : 494-, 1996

      87 P. K. DenBesten, 34 : 399-, 1989

      88 M. Yang, 272 : 13527-, 1997

      89 M. Yang, 273 : 17893-, 1998

      90 R. Gururajan, 52 : 101-, 1998

      91 J. Lohi, 276 : 10134-, 2001

      92 J. F. Woessner Jr., 22 : 33-, 2002

      93 H. Laronha, 9 : 1076-, 2020

      94 G. A. Rosenberg, 8 : 205-, 2009

      95 J. R. Backstrom, 16 : 7910-, 1996

      96 S. Rowsell, 319 : 173-, 2002

      97 E. Morgunova, 284 : 1667-, 1999

      98 P. A. Elkins, 58 : 1182-, 2002

      99 S. A. Watson, 9 : 325-, 1998

      100 R. G. Rempe, 36 : 1481-, 2016

      101 S. Lorenzl, 178 : 13-, 2002

      102 M. Hernandez-Guillamon, 290 : 15078-, 2015

      103 R. N. LePage, 377 : 267-, 1995

      104 P. Yan, 281 : 24566-, 2006

      105 P. J. Crouch, 108 : 1198-, 2009

      106 A. E. Roher, 205 : 1755-, 1994

      107 H. Mizoguchi, 331 : 14-, 2009

      108 M. Asahina, 20 : 60-, 2001

      109 M. A. Bruno, 68 : 1309-, 2009

      110 S. Horstmann, 22 : 966-, 2010

      111 B. Terni, 46 : 461-, 2015

      112 N. K. Lim, 26 : 779-, 2011

      113 S. Lorenzl, 43 : 191-, 2003

      114 N. A. Py, 6 : 247-, 2014

      115 S. Deb, 66 : 1642-, 1996

      116 K. J. Yin, 26 : 10939-, 2006

      117 A. M. Hartz, 43 : 514-, 2012

      118 L. A. Ridnour, 123 : 736-, 2012

      119 G. Meng, 12 : 31-, 2018

      120 C. -Y. Li, 13 : 1974-, 2018

      121 Y. Liu, 70 : 336-, 2018

      122 C. Moussa, 14 : 1-, 2017

      123 D. E. Lackey, 140 : 1502-, 2010

      124 R. J. Dalmolin, 41 : 1338-, 2007

      125 E. Y. Park, 57 : 66-, 2007

      126 G. S. Miranpuri, 24 : 74-, 2017

      127 G. S. Miranpuri, 26 : 60-, 2019

      128 N. Duman, 63 : 347-, 2018

      129 S. K. Halder, 28 : 2407-, 2013

      130 S. Li, 65 : 107-, 2019

      131 A. P. de Souza, 16 : 103-, 2000

      132 C. K. Underwood, 95 : 165-, 2003

      133 M. Bailey, 159 : 1981-, 2001

      134 N. Kim, 22 : 7697-, 2021

      135 N. N. Nalivaeva, 5 : 212-, 2008

      136 N. Iwata, 24 : 991-, 2004

      137 R. A. Marr, 23 : 1992-, 2003

      138 O. Lazarov, 120 : 7-, 2005

      139 김서화, "Vitamin D Inhibits Expression and Activity of Matrix Metalloproteinase in Human Lung Fibroblasts (HFL-1) Cells" 대한결핵및호흡기학회 77 (77): 73-80, 2014

      140 "Nucleotide. Accession No. NM_001349333.1, Homo sapiens FYN binding protein (FYB), transcript variant 4, mRNA," National Library of Medicine (US), National Center for Biotechnology Information

      141 Anna Więckowska, "Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease" American Chemical Society (ACS) 9 (9): 1195-1214, 2018

      142 윤상선, "Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer’s Disease" 한국응용약물학회 20 (20): 245-255, 2012

      143 H. Benson Peng, "Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice" Wiley 42 (42): 372-388, 2021

      144 Marta Martínez‐Bonet, "HIV‐1 increases extracellular amyloid‐beta levels through neprilysin regulation in primary cultures of human astrocytes" Wiley 234 (234): 5880-5887, 2019

      145 "Dementia"

      146 "Aducanumab"

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2008-01-01 평가 SCI 등재 (기타) KCI등재
      2006-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2004-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2001-07-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      1998-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.58 0.11 0.38
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.28 0.23 0.213 0.04
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼